GLP-1 receptor agonists were originally developed to help manage type 2 diabetes by enhancing insulin secretion and lowering blood sugar levels. Over time, these drugs have shown benefits far beyond glycemic control. They offer therapeutic benefits in obesity, cardiovascular health, kidney function, substance use disorders, and even neurodegenerative diseases.
As their influence grows, GLP-1 drugs are reshaping how consumers behave, how health is defined, and how businesses must respond.
Included in this report:
- Benefits of GLP-1 drugs beyond weight loss and diabetes treatments
- Shifting behaviour and preferences of GLP-1 consumers
- Impact on industries including pharma, food, supplements, and wellness
- Flawed assumptions about GLP-1 users
- The need for behavioral health support, functional nutrition, and wellness alternatives
- Industry-specific opportunities and emerging innovations
- Companies leading the shift in the GLP-1 era
- Actionable strategies for brands to align with GLP-1 consumer needs
